Zai discontinuing atopic dermatitis therapy

Zai Lab Ltd. (NASDAQ:ZLAB) said it will discontinue development of fugan (ZL-3101) to treat atopic dermatitis after it failed to meet the primary endpoint in a Phase IIa trial.

The double-blind, Chinese study enrolled 295 patients with mild to moderate subacute eczema. Zai said fugan "showed no difference compared to placebo" on the primary endpoint, which measured change in Eczema Area and Severity Index (EASI) at day 21...